Thoma Bravo Invests in Bluesight to Support Bluesight's Acquisition of Medacist

July 17, 2023

Thoma Bravo made a strategic growth investment in Bluesight to support Bluesight's acquisition of Medacist, combining two medication-management and drug-diversion analytics businesses into a single hospital pharmacy software platform. The combined company will expand Bluesight's medication intelligence capabilities and serve more than 2,000 hospitals across North America; committed financing was led by Monroe Capital and existing investor New Leaf Ventures remains invested. Financial terms were not disclosed.

Buyers
Thoma Bravo, Bluesight, Monroe Capital LLC
Targets
Medacist
Platforms
Bluesight
Location
Connecticut, United States
Transaction Type
Addon

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.